Not to be given as IM inj. Discontinue use if signs & symptoms of hypersensitivity including infusion-related & anaphylactic reactions occur; ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase or INR. Monitor liver function & eGFR prior to & during treatment. Not recommended to be used w/ chloroquine phosphate or hydroxychloroquine sulphate. May adversely affect renal function due to betadex sulfobutyl ether Na. Not to be used in patients w/ eGFR <30 mL/min. Determine liver function prior to treatment & monitor while in therapy. Not to be initiated in patients w/ ALT ≥5 times the upper limit of normal at baseline. Women of childbearing potential should use effective contraception during treatment. Not to be used during pregnancy. Discontinue breastfeeding or discontinue/abstain from therapy. Childn <12 yr & weighing <40 kg.
Sign Out
